Showing results (121-130 of 1,877) with videos related to
Sort By:
Pageof 188
Immunotherapy|December 5, 2022
The poorly immunogenic tumor microenvironment of pancreatic cancer: the impact of radiation therapy, and strategies targeting resistanceRobert Hughes, Adam E Snook, Adam C MuellerImmunotherapy|June 27, 2022
Federation of Clinical Immunology Societies Goes South 2021: advanced course on molecular and cellular translational immunologyBenjamin Diethelm-Varela, Antonia Reyes, Yvonne Rosenstein, et al.Immunotherapy|December 20, 2022
Systemic immune-inflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysisBao-Wen Tian, Ya-Fei Yang, Chun-Cheng Yang, et al.Immunotherapy|January 4, 2023
A new perspective on the potential application of RIPK1 in the treatment of sepsisXuesong Wang, Yan Chai, Zhe Guo, et al.Immunotherapy|January 11, 2023
Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITYEmanuel Raschi, Francesca Comito, Francesco Massari, et al.Immunotherapy|January 9, 2023
Super-refractory status epilepticus during blinatumomab initiation for B-cell acute lymphoblastic leukemiaChethan K Rao, Samuel Kamoroff, Julian Zorrilla, et al.Immunotherapy|January 25, 2023
FHL1 as a novel prognostic biomarker and correlation with immune infiltration levels in lung adenocarcinomaJingtao Zhang, Haitao Li, Minghao Guo, et al.Immunotherapy|January 7, 2021
Efficacy and safety of chimeric antigen receptor T cell immunotherapy in B-cell non-Hodgkin lymphoma: a systematic review and meta-analysisNa Wang, Yunchong Meng, Yaohui Wu, et al.Immunotherapy|January 7, 2021
The rationale for targeting the JAK/STAT pathway in scleroderma-associated interstitial lung diseaseRossella TalottaImmunotherapy|June 28, 2021
Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case reportFrancesco Fiorica, Lorenzo Belluomini, Jacopo Giuliani, et al.Pageof 188